$Singtel (Z74.SG)$ Regret selling at $2.38 back in February

$INTA (0192.MY)$
INTA's valuation has been in single-digit PE for a long time, and the revenue and profits in 2023 have reached a record high. The stock price has lacked momentum because it hasn't obtained contracts for a while, thus failing to attract investors.
As the saying goes: If you don't open for 3 years, it will take 3 years to recover. In April, INTA won a total of 3 construction contracts worth RM743 million, the Order Book reached a record high, and the stock price once broke the RM0.40 mark.
Assuming that the performance continues to grow in 2024 and 2025, a good ROI is expected in the future. INTA is similar to KSL in the industrial stocks, with a low valuation and in the process of valuation reassessment.

After reaching a historic closing high in its stock price in December last year, $Apple (AAPL.US)$ has seen a nearly 12% decline this year, erasing over $300 billion in market capitalization.
Some analysts with a pessimistic view believe that the stock, which did not maintain the support level of $180 last week and dipped below $170 during different times on Tuesday, might indicate a potential retracement to its October low of $1...

In February, NVIDIA's explosive earnings sparked a global stock market rally, with the $S&P 500 Index (.SPX.US)$ and $Dow Jones Industrial Average (.DJI.US)$ indices hitting new highs and the Nasdaq approaching a historic peak. Now, the U.S. stock market is poised for a series of significant events in March:
March 5, 2024, will mark "Super Tuesday" in the U.S. presidential election, the day of the primary elections. On this day, ...

The pharma giant $Eli Lilly and Co (LLY.US)$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...